



REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

Revance Therapeutics
Investor Relations Department
7555 Gateway Boulevard
Newark, CA 94560
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RVNC

Last Trade:	31.20
Trade Time:	4:00 PM ET Mar 19, 2018
Change:	0.20 ↑ (+0.645%)
Day Range	30.75 - 32.40
52-Week Range	18.43 - 37.45
Volume	378,613

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comp... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Mar 6, 2018 [Revance to Participate in Upcoming Investor Conferences](#)
- Feb 28, 2018 [Revance Releases Fourth Quarter and Full Year 2017 Results](#)
- Feb 28, 2018 [Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics](#)
- Feb 22, 2018 [Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018](#)
- Feb 14, 2018 [Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Mar 2, 2018 [Annual Report \(10-K\)](#)
- Mar 24, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 4, 2017 [Quarterly Report \(10-Q\)](#)
- May 9, 2017 [Quarterly Report \(10-Q\)](#)